Immunosuppression Increasing (2.23.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.
Autoimmune disease and pregnancy
EurekAlert!
For many aspiring mothers with autoimmune disease, pregnancy can be daunting and full of unknowns. In some cases, those suffering from specific autoimmune conditions have chosen to forego pregnancy altogether due to concerns about their disease treatments and adverse pregnancy outcomes.
Dead Words Eulogy
Editor's note: This is a bonus lecture provided to RheumNow Live 2024 registrants, and being shared with our RheumNow audience. Today is the last day to register to attend virtually (or in person); go to https://rheumnow.live/ for more information.
2023 Rheumatology Year in Review
Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.
2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.
Drug-Induced Dermatomyositis
A JAMA Dermatology systematic review of drug-induced dermatomyositis (DM) found the most commonly implicated agents include hydroxyurea, immune checkpoint inhibitors, statins and lipid-lowering agents, penicillamine, and tumor necrosis factor inhibitors.
Heritability of Osteoarthritis
A Swedish study examine the genetic contribution to various rheumatic/musculoskeletal diseases (RMDs) and showed that osteoarthritis (OA) had a large heritability compared with other RMDs.
New Year's Resolutions (1.5.2024)
Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
Editor's note: this article originally appeared March 14, 2023, and is being shared again as a Best of 2023. Enjoy!
Best of 2023: 25 Great Women in Rheumatology
Editor's note: this article originally appeared April 26, 2023, and is being shared again as a Best of 2023. Enjoy!
ICYMI: ACR Plenaries: Changing the Practice of Rheumatology
The Merriam-Webster definitions of “plenary” include: 1. complete in every respect: absolute, unqualified and 2. fully attended or constituted by all entitled to be present.
JAKi and TYK2i: What to use and when?
You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.
Social
#ACR24 - Day 3 Report
Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.
https://t.co/Dif4EUi30b https://t.co/4hfEJ1ef73
Dr. John Cush @RheumNow ( View Tweet )
1 year ago
In Vivo CAR T Cell Therapy.
A single intralymphatic injection of VivoVec™ particles:
- Generates functional CAR T cells in vivo
- Achieves complete B cell depletion in NHPs without lymphodepletion
- Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V
Links:
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year ago
Recommend "Triple Therapy" = Glucocorticoids + two other agents
Practically, that means MMF + belimumumab OR CNI for most pts
For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred
#ACR24 @RheumNow https://t.co/0gRISXSw0c
Mike Putman @EBRheum ( View Tweet )
1 year ago
Applying the #ACR24 #LupusNephritis: Case 2 by Dr M Dall’Era @RheumNow https://t.co/A7i103uHZT
Links:
TheDaoIndex @KDAO2011 ( View Tweet )
1 year ago
Lots of data on TYKs including much supporting efficacy in interferon inhibition
Can we really call interferon signalling a "central" pathway in SLE?
Inhibiting it has been modestly successful, at best, and mostly for skin dx
#ACR24 @RheumNow Abstr#2434 https://t.co/Q94FQz3gzO
Mike Putman @EBRheum ( View Tweet )
1 year ago
Class V #Lupus Nephritis usually takes longer to treat. Stay the course if no contraindications and taper steroids! - Dr A Askanase #ACR24 LN Guidelines @RheumNow https://t.co/4BBuAWi2da
Links:
TheDaoIndex @KDAO2011 ( View Tweet )
1 year ago
Dr. @karen_kc123 discusses the results of the VITAL study.
- Long term use of Vit D3 2000IU was safe and decreased the incidence of all autoimmune dses by 22%.
- It took a while to work but the effect dissipates once discontinued.
@RheumNow #ACR24
@rheumarhyme https://t.co/mnwRsdZ06N
Links:
sheila @RHEUMarampa ( View Tweet )
1 year ago
In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #SLE
@RheumNow #ACR24 @rheumarhyme https://t.co/PvjjmhHaOd
sheila @RHEUMarampa ( View Tweet )
1 year ago
We know most preexisting autoimmune disease is very mangaeable when checkpoint inhibitors are needed.
So great to see that, in the VA, autoimmune disease pts largely haven't missed out on potentially lifesaving cancer immunotherapy.
Keep on reassuring!
#ACR24 ABST1985 @RheumNow https://t.co/ApOACBLi4K
David Liew @drdavidliew ( View Tweet )
1 year ago
What a result!!!
Crowed split 49% against and 51% for MCTD as a unique disease entity
Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group
Fantastic session from all the presenters
@RheumNow #ACR24 https://t.co/GgTVQ1VNWP
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
1 year ago
